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Abstract
Background:  D-dimer is considered a marker of hypercoagulable state and of endogenous
fibrinolysis, so increased d-dimer is detectable in patients affected by thrombosis. Yet, several
studies showed that also infertility, in particular secondary infertility due to recurrent fetal losses,
has been often related to thrombotic events, in particular in women carrying thrombotic risk
factors such as inherited thrombophilia (MTHFRC677T, PTHRA20210G, Factor V Leiden
polimorphisms and/or inhAfter this screening we selected 39erited protein C, protein S, AT III
deficiency) or acquired thrombophilia (primary antiphospholipid syndrome, acquired protein C,
protein S, AT III deficiency, drugs induced thrombophilia). However, because its high predictive
negative value in case of suspected thrombosis, increased d-dimer has been often associated to
subclinical thrombophilia. The aim of this study is to investigate the role of d-dimer as first marker
of thrombophilia in women affected by unexplained infertility and subsequently to search the cause
of increased d-dimer, such as inherited and/or acquired thrombophilia.
Patients and Methods: We selected 79 patients with unexplained primary or secondary
infertility. We excluded 40 patients affected by hydrosalpinx, uterine fibroids, uterine
malformations, endocrinological and immunological diseases, luteal insufficiency, cytogenetical
alterations. All remaining 39 patients were tested for d-dimer and divided in two groups: the
patients of group A (25 patients) showed increased plasma d-dimer, in group B were included 14
patients with normal plasma level of d-dimer. After this step all 39 patients were screened for
MTHFRC677T, PTHRA20210G, Factor V Leiden polimorphisms, protein C, protein S, AT III,
anticardiolipin IgM and IgG, lupus anticoagulant. In the control group were included 15 age matched
women without sterility problems referred to our outpatient's section of vascular medicine for
suspected deep venous thrombosis.
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Statistical analysis was based on χ2 test, differences were considered to be significant if p < 0.05.
Results: D-dimer was increased in 25/39 and 20/25 showed inherited/acquired thrombophilia
while patients with normal d-dimer showed inherited/acquired thrombophilia in 7/14 (p: < 0.05, s).
Discussion: D-dimer is a well known marker of hypercoagulable state, in particular its high
predictive negative value in case of suspected thrombosis has been recognised by several reports.
Yet, increased d-dimer has been identified also for subclinical thrombophilia besides for vascular
thrombosis. Our data, in fact, for the first time suggest an interesting role of d-dimer to identify
women affected by unexplained primary or secondary infertility and thrombophilia. So, probably
there is a role for d-dimer in these subjects for its predictive positive value. Of course, further data
on large based population are needed to confirm our results, because these findings may speed up
a diagnostic screening in these patients also for a good cost/effectiveness of this test.
Introduction
D-dimer is considered a marker of hypercoagulable state
besides of endogenous fibrinolysis, so increased d-dimer
is detectable in patients affected by arterial and/or venous
thrombosis [1]. Yet, several studies showed increased d-
dimer also in patients affected by subclinical throm-
bophilia without ongoing thrombosis [2]. Moreover, also
in other clinical conditions, such as chronic inflammation
as infectious disease (also as marker of disseminated
intravascular coagulation if sepsis is associated) as cancer
as necrosis as eldership and pregnancy we may observe an
increase of plasma d-dimer [3-8]. So, for this reason d-
dimer test is usually used in clinical management for its
high predictive negative value in suspected thrombosis,
particularly in deep vein thrombosis (DVT) [9-11]. How-
ever, several studies showed that frequently women
affected by sterility, in particular secondary sterility for
recurrent foetal losses, may be affected by an underlying
inherited and/or acquired thrombophilia [12-20].
Besides, common thrombotic risk factors which include
also a bad lifestyle (e.g. obesity, non regard to Mediterra-
nean diet, sedentary life), a lot of molecular thrombotic
risk factors such as inherited or acquired clotting inhibitor
deficiency (i.e. protein C, protein S, antithrombin III),
inherited thrombophilia (factor V Leiden, prothrombin
A20210G mutation), primary or secondary hyperhom-
cysteinemia, primary or secondary antiphospholipid syn-
drome and increased plasma factor VIII levels have been
identified [21]. Furthermore, these molecular alterations
may be also associated in some subjects so inducing gene-
gene interactions and/or gene-enviromental interactions
[22-24]. So, because the high incidence of clotting abnor-
malities in these patients, according to the data of Brenner
et al. [24,25], we investigated the role of d-dimer as first
marker of thrombophilia in women affected by sterility in
order to identify causes of increased d-dimer and proba-
bly of the induced sterility.
Patients and Methods
We selected 79 women affected by primary or secondary
sterility (due to three or more fetal losses) referred to our
sterility center. We excluded 40 patients affected by hydro-
salpinx, uterine fibroids, uterine malformations, luteal
insufficiency, anovulation, cytogenetical alterations,
infectious diseases, endocrinological diseases (ie diabetes,
subpituitarism), and by immunological diseases (inher-
ited and/or acquired immunodeficiency, rheumatoid
arthritis, systemic lupus erythematosus, systemic sclerosis,
vasculitis).
After this screening we selected 39 patients (12 affected by
primary sterility and 27 by secondary sterility due to recur-
rent foetal loss). These 39 patients were tested for d-dimer.
D-dimer was measured by several methods [26]; d-dimer
were tested randomly in various periods of the ovarian
menstrual cycle in 31 patients, in one patient during men-
strual bleeding and in seven patients during hormonal
therapy in order to obtain controlled ovarian hyperstimu-
lation (COH). Following d-dimer examination patients
were divided in two different groups: group A including
25 patients with increased d-dimer levels and group B
including 14 patients with normal d-dimer levels. As con-
trol group we selected 15 age-matched women, without
sterility problem in their anamnesis, referred to our out-
patient's section of vascular medicine for suspected deep
venous thrombosis.
Subsequently d-dimer evaluation, in order to identify a
possible inherited and/or acquired thrombophilia, all
patients were screened for methilene-tetra-hydro-folate-
reductase C677T gene polimorphism (MTHFRC677T), Fac-
tor V Leiden gene polimorphism (FVL), prothrombin
A20210G gene polimorphism (PTHRA20210G), protein S
deficiency, protein C deficiency, antithrombin III defi-
ciency (AT III), lupus anticoagulant, IgM and/or IgG anti-
cardiolipin autoantibodies [22,27]. Moreover, all patients
showing increased d-dimer were tested also for β-human-
corionic-gonadotropin (β-HCG) to exclude early preg-Journal of Translational Medicine 2004, 2:38 http://www.translational-medicine.com/content/2/1/38
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nancy, and lower limb ultrasound vascular examination
associated to compression ultrasonography (CUS) to
exclude a lower limb deep venous thrombosis (DVT);
both conditions, in fact, are well known conditions asso-
ciated to increased d-dimer [4,9-11].
Furthermore, patients with increased d-dimer (group A,
25 patients) and patients with normal d-dimer (group B,
14 patients) were compared also for possible differences
in molecular markers of inherited and/or acquired throm-
bophilia.
Statistical analysis was based on χ2 test, differences were
considered to be significant if p < 0.05.
Results
We found thrombophilia in group A, 80%, and in group
B, 50%, so thrombophilia rate in all 39 selected was 65%
if we consider together group A (i.e. women affected by
sterility and showing increased d-dimer) and group B (i.e.
women affected by sterility with normal d-dimer levels)
(table 1, 'see additional file 1').
Twenty patients of group A (80%) affected by sterility with
increased d-dimer levels, showed inherited and/or
acquired thrombophilia [(six MTHFRC677T homozygosity,
four FVL heterozygosity, five PTHRA20210G heterozygosity,
three inherited Protein S deficiency, two showing com-
bined defects (one MTHFRC677T homozygosity associated
to protein S deficiency and one MTHFRC677T homozygos-
ity associated to FVL heterozygosity), none protein C defi-
ciency or AT III deficiency, none positive for the presence
of lupus anticoagulant, none with increased anticardioli-
pin autoantibodies IgM and/or increased anticardiolipin
autoantibodies IgG)] (table 2, 'see additional file 2').
Remaining five women of the group A did not show
molecular thrombophilia, but in their anamnesis we
found some possible correlation with an acquired throm-
bophilia: controlled ovarian hyperstimulation in one
patient, monthlies in one patient, early pregnancy in one
patient, miscarriage in one patient, none apparent cause
in 1 patient; among them two of these five patients were
heterozygous for MTHFRC677T. Furthermore, two patients
of group A carrying inherited thrombophilia for the pres-
ence of heterozygous FVL and increased d-dimer revealed
previous DVT with following pulmonary embolism in
their anamnesis. Data of patients of group A are summa-
rised in table 2 ('see additional file 2').
Seven patients of group B (50%) showed inherited and/or
acquired thrombophilia (one MTHFRC677T homozygosity,
one FVL heterozygosity, five PTHRA20210G heterozygosity,
none inherited Protein S deficiency, protein C deficiency,
AT III deficiency, none presence of lupus anticoagulant,
none with increased anticardiolipin autoantibodies IgM
and/or IgG), as reported in table 2 ('see additional file 2').
All remaining seven patients of group B showed all heter-
ozygosity for MTHFRC677T. Moreover, none patients of
group B revealed previous DVT and/or pulmonary embo-
lism.
Five patients of group C (i.e. control group) (33.3%)
showed increased d-dimer as molecular markers of ongo-
ing proximal DVT confirmed by ultrasound vascular
examination associated to CUS; moreover, all five patients
revealed an underlying inherited and/or acquired throm-
bophilia (three MTHFRC677T homozygosity, one protein S
deficiency, one combined thrombophilia: FVL heterozy-
gosity associated to protein S deficiency). Data of patients
of group C are summarised in table 2 ('see additional file
2').
In all groups positivity for anticardiolipin antibodies or
lupus anticoagulant mimicking a primary antiphospholi-
pid syndrome (APS) was not discovered.
So, as showed in table 3 ('see additional file 3'), increased
d-dimer is frequently associated with thrombophilia in
women affected by sterility, while this association is less
present in patients with normal d-dimer, and this differ-
ence reaches statistical significance (p < 0.05); further-
more thrombophilia is more frequent in group A than in
control group (i.e. group C) and also this difference
reaches statistical significance (p < 0.05); finally, throm-
bophilia in group B is more frequent than in control
group (i.e. group C), but this difference does not reach sta-
tistical significance (p: 0.08, ns).
Discussion
In this report for the first time the role of d-dimer was
investigated in diagnostic screening of patients affected by
sterility and this is a really innovative data available in this
clinical setting.
D-dimer is a fibrin degradation product which usually is
extensively screened in patients with suspected thrombo-
sis and/or pulmonary embolism [9]. An increased plasma
d-dimer might have a predictive positive value for DVT
and/or pulmonary embolism, but because increased d-
dimer has been observed also in several conditions not
associated with ongoing thrombosis (malignancy,
chronic inflammation, infections, acute coronary syn-
dromes, necrosis, eldership) [3-9] the really interesting
role of d-dimer in this clinical setting is for its high nega-
tive predictive value as reported by Bounameaux et al. in
a series of patients with suspected pulmonary embolism
[9]. However, increased d-dimer has been observed also
in subjects affected by thrombophilia (i.e. inherited
thrombophilia and/or acquired thrombophilia) showingJournal of Translational Medicine 2004, 2:38 http://www.translational-medicine.com/content/2/1/38
Page 4 of 6
(page number not for citation purposes)
hypercoagulable state without ongoing thrombosis as
reported by Arkel et al. and Humphries et al. [2,23].
So, our data showed that patients of group A, carrying
increased d-dimer, has been extensively screened for
inherited and/or acquired thrombophilia and 80% of
them revealed a well known molecular condition associ-
ated to hypercoagulable state which may explain
increased d-dimer levels (table 2, 'see additional file 2').
Moreover, this our clinical and laboratory screening
reaches statistical significance compared to group B and
group C (table 3, 'see additional file 3'). Furthermore, five
patients with increased d-dimer did not reveal inherited
and/or acquired thrombophilia, but a thorough anamne-
sis and a clinical evaluation permitted to identify other
causes of increased d-dimer in four of these patients: one
patient showed early pregnancy (confirmed by β-HCG
measurements and following ultrasound scan), a known
condition associated to hypercoagulability and increased
d-dimer [4,28,29], one patient revealed an early abortion,
confirmed by following decrease of β-HCG, and increased
dimer levels might be related to uteroplacental thrombo-
sis and/or necrosis [30], one patient was ongoing to con-
trolled ovarian stimulation and this condition may be
associated to alteration of haemostasis with a trend
toward thrombophilia [31,32] and one patient showed
ongoing monthlies, a condition associated to wound
healing which involves also clotting factors and might
explain increased d-dimer [33]; remaining one patient
showed increased d-dimer for unknown causes probably
related to not well studied thrombophilia [34] or idio-
pathic thrombophilia and/or other conditions although
we excluded in our selection criteria several other diseases
associated to increased d-dimer.
So for the first time we showed an interesting and relevant
role of d-dimer in the screening of sterility causes, partic-
ular an underlying thrombophilia may be suspected in
pathophysiology of sterility if plasma d-dimer is
increased. However, also an evaluation of other condi-
tions associated to increased d-dimer (e.g. chronic inflam-
mation, immunopathological diseases, infectious
diseases, cancer, necrosis, eldership, pregnancy, control-
led ovarian stimulation, monthlies) should be performed
in order to avoid a misinterpretation.
Also group B, with normal d-dimer levels, showed an
increased rate of thrombophilia (50%, table 1, 'see addi-
tional file 1'), so confirming one more time the clear rela-
tionship between thrombophilia and sterility, even if
these data did not reach statistical significance compared
to group C (table 3, 'see additional file 3'). Yet, patients of
group B, although affected by thrombophilia and sterility
did not show increased d-dimer. This finding might be
explained by several causes and a laboratory mistake can-
not be excluded; furthermore, these patients of group B
may show also transient and/or silent thrombophilia
which may trigger a hypercoagulable state if associated to
other causes (i.e. acquired conditions associated to throm-
bophilia) during their natural history and our evaluation
of d-dimer might be done during a not-hypercoagulable
transient state.
An extensive screening of causes of increased d-dimer in
our population was also performed. The association
between thrombophilia and sterility due to recurrent foe-
tal loss is well known as reported by several reports [12-
20] and also by our data. However, recently an association
between primary sterility and thrombophilia has been
underlined such as also between thrombophilia and
repeated in vitro fertilisation failures [35,36].
A clear relationship between thrombophilia and recurrent
foetal loss has been reported for inherited deficiency of
clotting inhibitors (i.e. protein C deficiency, protein S
deficiency, AT III deficiency) [20,36], but we did not find
in our population this strong association (only four cases
of protein S deficiency, one of these associated to
MTHFRC677T homozygosity, and none case of protein C
deficiency and/or AT III deficiency). However, this aspect
seems to be in agreement with other reports in which
other thrombophilic conditions were more frequent than
clotting inhibitor deficiencies (e.g. FVL, MTHFRC677T
homozygosity, antiphospholipid syndrome and so on)
[12-20].
FVL gene polymorphism has been frequently found in
women affected by recurrent fetal loss, although the fre-
quency of FVL differs in each study [15,24]. These differ-
ences could be related, besides to ethnic background, also
to different inclusion criteria of investigated patients.
However, FVL is associated to sterility also in our study
(four cases in group A and one case in group B; table 2,
'see additional file 2').
An increased MTHFRC677T homozygosity has been found
in our study population (six cases in group A and one case
in group B), so confirming a clear role of homocysteine
metabolism and of the related hypercoagulable state in
sterility pathophysiology [38-40]. Of course, MTHFR gene
polymorphism and related homocysteine metabolism
may influence sterility also through folic acid and vitamin
B12 deficiency due to uncorrected diet and/or lifestyle
[41].
We found also an increased frequency of PTHRA20210G in
women affected by sterility (five cases in group A and five
cases in group B), and these data seem to be different from
data reported by Pickering et al [42] and Deitcher et al
[43] and in agreement with data reported by Brenner et alJournal of Translational Medicine 2004, 2:38 http://www.translational-medicine.com/content/2/1/38
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[24,25]. As we previously underlined, these differences
could be related to inclusion criteria established by Inves-
tigators of each study and also to an ethnic background;
this gene polymorphism, in fact, is more frequent in
Southern Europe than in Northern Europe [44,45].
A really interesting data is the absence of APS from our
study population and this data differs from data of the Lit-
erature. A possible explanation could be offered by differ-
ent selection criteria: we exclude, in fact, women with
immunopathological diseases (e.g. rheumatoid arthritis,
systemic lupus erythematosus, systemic sclerosis, vasculi-
tis), so excluding the most common causes of secondary
APS and so searching only primary APS that is more rare
than primary [46].
In conclusion, in this investigation both groups of women
affected by sterility, group A and B, showed increased inci-
dence of thrombophilia compared to control group
(group A vs group C, p: < 0.05, s; group B vs group C, p:
0.08, ns; table 3, 'see additional file 3'), so confirming,
one more time the relevant role of thrombophilia in
pathophysiology of sterility. So, the first relevant data we
offer in this study is the role of d-dimer in the screening of
sterility causes in order to early suspect an underlying
thrombophilia; this screening, as also showed by our data,
is in agreement with an elevated frequency of throm-
bophilia in women affected by sterility (80 % in group A,
50% in group B, 65% if we consider together group A and
B). Of course, although several Authors already reported
the association between thrombophilia and recurrent foe-
tal loss we may testify that probably the role of throm-
bophilia is an underestimated problem if we consider all
sterility conditions because usually thrombophilia is
screened only for repeated foetal loss and not screened in
any case of unexplained sterility as in this study.
So, based on our data further studies on large population
are needed not only to confirm our results but also to
focus a possible different prognosis of these groups, in
particular to sterility prognosis.
Conclusion
Our data demonstrated a clear role of thrombophilia in
patients affected by sterility, but suggesting a clear diag-
nostic role of increased d-dimer in a lot of these patients.
This diagnostic screening of thrombophilia in women
affected by sterility, based on the d-dimer levels, may also
represent a really speed method to suspect thrombophilia
in these subject and has also a good cost/benefit ratio,
although other causes of increased d-dimer should be
always considered. In a second step, if increased d-dimer
levels are present causes of hypercoagulable state may be
investigated (i.e. inherited thrombophilia and/or
acquired thrombophilia). This approach may play a role
not only in differential diagnosis of sterility but also in the
early diagnosis of sterility due to thrombophilia. After the
first step in which d-dimer may be evaluated, causes of
increased d-dimer should be subsequently identified in
order to start a possible antithrombotic treatment soon.
Nevertheless thrombophilia may be present in few cases
also in subjects with normal d-dimer, it should be investi-
gated always if other causes of sterility are not present.
So, we strongly suggest to test d-dimer in patients affected
by sterility as first step of a possible underlying throm-
bophilia in order to early identify the cause of throm-
bophilia and its prompt treatment but other data should
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